Pancreatitis
Novel blood test could be first step to early detection of pancreatic cancer
A novel, rapid blood test demonstrated potential for detecting early-stage pancreatic cancer, according to results of a retrospective study.
The year in lipids: Progress in Lp(a) management and a blow to the ‘HDL hypothesis’
In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention of major adverse CV events.
‘Significant’ savings with diclofenac vs. indomethacin for post-ERCP pancreatitis
PHILADELPHIA — No significant differences were observed in post-endoscopic retrograde cholangiopancreatography pancreatitis with prophylactic diclofenac vs. indomethacin, with researchers also reporting savings of nearly $133,000.
Plozasiran lowers triglycerides, reduces pancreatitis risk in chylomicronemia
In patients with persistent chylomicronemia, plozasiran, a small interfering RNA therapy, was associated with lower triglyceride levels and reduced risk for pancreatitis, researchers reported at the European Society of Cardiology Congress.
Tirzepatide tied to lower odds for diabetic retinopathy, pancreatitis than GLP-1s
Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter.
Plozasiran secures FDA breakthrough status for FCS, closing gap with rival olezarsen
The FDA has granted breakthrough therapy designation to Arrowhead Pharmaceuticals’ plozasiran, coupled with diet, to decrease triglycerides in patients with familial chylomicronemia syndrome, according to a company release.
Q&A: Petition asks FDA to revise fenofibrate labeling to emphasize no CV outcome benefits
Because the science underpinning medicine evolves so quickly, it is not uncommon for some doctors to manage patients based on old evidence that is no longer a best practice; this is called clinical inertia.
Olezarsen safely lowers triglycerides in patients with familial chylomicronemia syndrome
Olezarsen, an antisense oligonucleotide targeting mRNA for apolipoprotein C-III, lowered triglycerides at 6 months for patients with familial chylomicronemia syndrome without excessive adverse events, researchers reported.
Olezarsen safely lowers triglycerides in patients with familial chylomicronemia syndrome
Olezarsen, an antisense oligonucleotide targeting mRNA for apolipoprotein C-III, lowered triglycerides at 6 months for patients with familial chylomicronemia syndrome without excessive adverse events, researchers reported.
Olezarsen reduces triglycerides, pancreatitis events in familial chylomicronemia syndrome
Monthly olezarsen 80 mg significantly lowered triglyceride levels and also reduced incidence of acute pancreatitis vs. placebo in patients with familial chylomicronemia syndrome, according to a study in The New England Journal of Medicine.